---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-025232"
form_type: "8-K"
ticker: "PEPG"
cik: "0001835597"
company_name: "PepGen Inc."
filed_at: "2025-02-24T23:59:59+00:00"
generated_at: "2026-05-26T06:23:50.706476+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# PepGen reports robust splicing correction in DM1 trial; 29.1% mean correction at 10 mg/kg single dose

## Summary
- Mean splicing correction of 12.3% (5 mg/kg, n=6) and 29.1% (10 mg/kg, n=4) at 28 days post single dose.
- Favorable emerging safety profile; one treatment-related SAE of abdominal pain potentially confounded.
- Cash $120.2M as of Dec 31, 2024, expected to fund operations into 2026.
- Net loss $90.0M for FY2024 ($2.85/share) vs $78.6M ($3.30/share) in FY2023.
- 15 mg/kg cohort results expected H2 2025; CONNECT1-EDO51 10 mg/kg fully enrolled with results Q3 2025.

## SEC filing metadata
- accession: 0000950170-25-025232
- form_type: 8-K
- ticker: PEPG
- cik: 0001835597
- company_name: PepGen Inc.
- filed_at: 2025-02-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835597/000095017025025232/0000950170-25-025232-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835597/000095017025025232/pepg-20250224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-025232
- JSON: https://secwatch.observer/filing/0000950170-25-025232.json
- Plain text: https://secwatch.observer/filing/0000950170-25-025232.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.